Drug Trial Radar · NCT02974010
Sequential Therapy for the Treatment of Severe Bipolar Depression.
Last checked: Nov 19, 2026Latest source record: May 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Jan 15, 2018
Primary completion
Aug 31, 2018
Study completion Nov 20, 2019
Sponsor
- Lead sponsor
- NeuroRx, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Massachusetts General Hospital; Target Health Inc.
- First posted
- Nov 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
NeuroRx is developing NRX-101, a fixed-dose combination oral capsule composed of d-cycloserine (DCS) and lurasidone for the maintenance of remission from Severe Bipolar Depression with Acute Suicidal Ideation (C-SSRS level 4 or 5) or Behavior (ASIB) in following initial stabilization. Patients with Severe Bipolar Depression and ASIB will be recruited in both inpatient and outpatient settings and, following informed consent, will be given an intravenous infusion of ketamine 0.5mg/kg over 40 minutes. Those who exhibit a satisfactory clinical response to ketamine will be randomly allocated to NRX-101 or to lurasidone alone (the comparator group). This study is conducted as a feasibility study for a pivotal phase 2b/3 clinical trial and the primary outcomes for this phase 2 study were blood levels of NRX-101, in order to confirm pharmaco-kinetics with remission from depression, as measured by BISS-derived MADRS and relapse as secondary outcomes.
Conditions
- Bipolar Depression
- Suicidal Ideas
- Suicidal Ideation
- Suicide, Attempted
Interventions
NRX-101 Oral CapsuleDrug
Prospective Randomized Factorial Design Study as per arm/group descriptions
Lurasidone Oral CapsuleDrug
Prospective Randomized Factorial Design Study as per arm/group descriptions
Ketamine Intravenous InfusionDrug
Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
Saline Solution Intravenous InfusionDrug
Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
Primary outcomes
What the sponsor says the trial is designed to measure.
- BDM Score (BISS-derived MADRS) Change From Baseline at Day 42Time frame: Day 42
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Research Site, Birmingham
Birmingham, Alabama
Research Site, Fort Lauderdale
Fort Lauderdale, Florida
Research Site, Charlotte
Charlotte, North Carolina
Research Site, Houston
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.